Product inhibited from decreasing in content of prostaglandin f2α derivative
The use of a thermoplastic resin container with a specific cyclic polyolefin composition addresses the issue of PGF2α derivative adsorption and content decrease, ensuring effective storage and stability for glaucoma and ocular hypertension treatments.
Patent Information
- Application Number
- PCT/JP2024/017344
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-11
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-14
AI Technical Summary
Prostaglandin F2α derivatives used in treating glaucoma and ocular hypertension tend to adsorb to storage containers, leading to a decrease in their content, which is undesirable.
Storing an aqueous solution containing PGF2α derivatives in a thermoplastic resin container with a specific cyclic polyolefin composition effectively suppresses adsorption and content decrease, even under varying storage conditions.
The use of a thermoplastic resin container with a specific cyclic polyolefin composition significantly reduces the adsorption of PGF2α derivatives to the container, effectively maintaining their content over time, particularly at elevated temperatures.
Smart Images

Figure JPOXMLDOC01-APPB-C000002 
Figure JPOXMLDOC01-APPB-M000003 
Figure JPOXMLDOC01-APPB-T000001
Abstract
Description
A product that prevents the content of prostaglandin F2α derivatives from decreasing
[0001] The present invention relates to a product in which an aqueous liquid preparation containing a prostaglandin F2α (PGF2α) derivative is stored in a thermoplastic resin container containing a specific cyclic polyolefin, thereby preventing a decrease in the content of the prostaglandin F2α derivative.
[0002] PGF2α derivatives are used to treat glaucoma and ocular hypertension. However, PGF2α derivatives tend to be adsorbed to eye drop containers used to store aqueous formulations, which undesirably reduces the content of the PGF2α derivative. A method for effectively suppressing such adsorption of PGF2α derivatives to storage containers is desired.
[0003] Patent Document 1 describes that by incorporating polyethylene glycol monostearate into an eye drop containing latanoprost, a PGF2α derivative, adsorption of latanoprost to a storage container is suppressed. Patent Document 2 also describes an eye drop in which an aqueous solution containing a fluorine-containing prostaglandin derivative is stored in an ethylene oxide gas sterilized container to suppress a decrease in its content. However, it is not known that storing an aqueous solution containing a PGF2α derivative in a thermoplastic resin container containing a specific cyclic polyolefin can suppress a decrease in the content of the PGF2α derivative.
[0004] JP 2009-040749 A JP 2011-063625 A
[0005] The present invention aims to provide a product in which an aqueous liquid preparation containing a PGF2α derivative is stored in a thermoplastic resin container containing a specific cyclic polyolefin, thereby suppressing the decrease in the content of the PGF2α derivative.
[0006] As a result of intensive research to solve the above problems, the present inventors have found that by storing an aqueous liquid preparation containing a PGF2α derivative in a thermoplastic resin container containing a specific cyclic polyolefin, it is possible to suppress adsorption of the PGF2α derivative to the container under various conditions (e.g., storage conditions at 40°C or 60°C). Furthermore, it has been found that the container can also effectively suppress a decrease in the content of the PGF2α derivative. Based on the above findings, the present inventors have further conducted research and have completed the present invention.
[0007] The present invention relates to the following [1a], [5a], [11a], and [1] to
[11] . [1a] A product in which an aqueous liquid preparation containing a prostaglandin F2α derivative is stored in a thermoplastic resin container containing a cyclic polyolefin. [1] A product in which the aqueous liquid preparation containing a prostaglandin F2α derivative is stored in a thermoplastic resin container containing a cyclic polyolefin, thereby suppressing a decrease in the content of the prostaglandin F2α derivative. [2] The product according to [1a] or [1], in which the prostaglandin F2α derivative is one or more selected from the group consisting of tafluprost, latanoprost, isopropyl unoprostone, travoprost, and bimatoprost. [3] The product according to [1a], [1], or [2], in which the prostaglandin F2α derivative is tafluprost. [4] The product according to any one of [1a] and [1] to [3], wherein the thermoplastic resin container is a polymer composition containing 72% by weight or more of a cyclic polyolefin having hydrogenated aromatic vinyl polymer block units, which are hydrogenated products of polymer blocks composed of aromatic vinyl monomer units, and hydrogenated conjugated diene polymer block units, which are hydrogenated products of polymer blocks composed of conjugated diene monomer units. [5a] The product according to [4], wherein the polymer composition contains 2% by weight or more and 25% by weight or less of a resin obtained by hydrogenating a C9 petroleum resin. [5] The product according to [4], wherein the polymer composition contains 2% by weight or more and 25% by weight or less of an alicyclic saturated hydrocarbon polymer. [6] The product according to [4], [5a], or [5], wherein the polymer composition contains 2% by weight or more and 25% by weight or less of a styrene-based block copolymer. [7] The product according to any one of [1a], [5a], and [1] to [6], wherein the hydrogenated aromatic vinyl polymer block unit constituting the cyclic polyolefin is a hydrogenated polystyrene block unit which is a hydrogenated product of a polystyrene block unit composed of a styrene monomer unit, and the hydrogenated conjugated diene polymer block unit constituting the cyclic polyolefin is a hydrogenated butadiene polymer block unit which is a hydrogenated product of a butadiene polymer block composed of a butadiene monomer unit. [8] The product according to any one of [1a], [5a], and [1] to [7], wherein the product is an eye drop.[9] The product according to any one of [1a], [5a], and [1] to [8], wherein the aqueous liquid preparation contains a surfactant.
[10] A method for suppressing a decrease in the content of a prostaglandin F2α derivative in an aqueous liquid preparation by storing the aqueous liquid preparation containing the prostaglandin F2α derivative in a thermoplastic resin container containing a cyclic polyolefin. [11a] A thermoplastic resin container for storing an aqueous liquid preparation containing a prostaglandin F2α derivative, comprising a cyclic polyolefin and a hydrogenated C9 petroleum resin and / or a styrene-based block copolymer.
[11] A thermoplastic resin container for storing an aqueous liquid preparation containing a prostaglandin F2α derivative, comprising a cyclic polyolefin and an alicyclic saturated hydrocarbon polymer and / or a styrene-based block copolymer.
[0008] According to the present invention, it is possible to suppress the adsorption of the PGF2α derivative to the container over time, and further to effectively suppress the decrease in the content of the PGF2α derivative.
[0009] [Aqueous solution containing PGF2α derivative] The prostaglandin F2α derivative (PGF2α) of the present invention may be an aqueous solution, preferably an aqueous solution for medical use, more preferably an aqueous solution for ophthalmology, and even more preferably a PGF2α derivative that can be used as eye drops.The PGF2α derivative of the present invention is characterized by being easily adsorbed to a container.Preferred examples of such PGF2α derivatives include those suitable for ophthalmology, such as tafluprost, latanoprost, isopropyl unoprostone, travoprost, and bimatoprost.Their chemical structural formulas are as shown in Table 1 below, and they have a common chemical structure.
[0010] The PGF2α derivative of the present invention preferably has a molecular weight in the range of about 350 to 550, more preferably about 400 to 520, but is not limited thereto. A preferred example of the molecular formula of the PGF2α derivative of the present invention is CxHyOz (x: 20 to 30, y: 30 to 40, z: 4 to 6), which may further contain a fluorine atom or a nitrogen atom in the molecule. Preferably, the compound further contains 1 to 6 fluorine atoms in the molecule, more preferably 2 to 3 fluorine atoms in the molecule, and may further contain 1 to 2 nitrogen atoms or sulfur atoms in the molecule, but is not limited thereto.
[0011] In the product of the present invention, the amount of the PGF2α derivative to be blended is 0.0001 w / v % to 0.2 w / v % relative to the total amount of the aqueous liquid preparation, preferably 0.001 w / v % or more, more preferably 0.0015 w / v % or more, but is not limited thereto.
[0012] Eye drops containing the PGF2α derivative of the present invention are typically used for the treatment of glaucoma and ocular hypertension, but are not limited thereto. "Treatment" means alleviating or curing a symptom or disease and / or its associated symptoms. Glaucoma is an eye disease characterized by progressive optic nerve damage and is considered to be one of the major causes of blindness. Ocular hypertension is a disease in which abnormally elevated intraocular pressure occurs, but no abnormality or damage occurs in the optic nerve. The PGF2α derivative of the present invention may also be used in combination with known β-blockers, α2 agonists, or Rho-kinase inhibitors, such as timolol maleate, carteolol hydrochloride, brimonidine tartrate, or ripasudil hydrochloride hydrate, or combinations thereof.
[0013] [Thermoplastic Resin Container Comprising a Specific Cyclic Polyolefin] In the present invention, a thermoplastic resin container comprising a specific cyclic polyolefin (hereinafter also referred to as SB) is used to store aqueous liquid preparations, preferably eye drops. It is preferably used for ophthalmic or eye drop containers, medicine bottle ampoules, vial bodies, caps and nozzles used therefor, or ophthalmic test tubes, blood collection tubes, specimen containers, prefilled syringes, syringes, etc. It may be a multi-dose eye drop container capable of storing an aqueous liquid preparation containing the above-mentioned active ingredient (PGF2α derivative). A "multi-dose eye drop container" is a storage container that can be restored to a sealed state after opening to a portable state, allowing repeated use of eye drops from the same container over a period of repeated use, for example, several days to several months (preferably several days to about one month). The internal volume of the container is preferably, but not limited to, approximately 1 mL to 20 mL, more preferably 1 mL to 8 mL. The shape of the container is not particularly limited, and the shape of a storage container typically used for eye drops can be used. The container may be a light-proof container. The container may be sterilized. Examples of such sterilization methods include, but are not limited to, electron beam (EB) sterilization, ethylene oxide gas (EOG) sterilization, hydrogen peroxide (H2O2) gas sterilization, and gamma ray sterilization. Preferably, the container of the present invention is made of a material suitable for preventing the PGF2α derivative from being adsorbed to the container, and another preferred feature is that the container is made of a material suitable for preventing a decrease in the content of the PGF2α derivative, but is not limited to these.
[0014] The thermoplastic resin container described above is a composition containing a specific cyclic polyolefin (A) (hereinafter, sometimes referred to as "component (A)"), and may additionally contain an alicyclic saturated hydrocarbon polymer (B) (hereinafter, sometimes referred to as "component (B)") and a styrene-based block copolymer (C) (hereinafter, sometimes referred to as "component (C)").
[0015] <Cyclic Polyolefin (A) (Component (A))> The cyclic polyolefin (A) of the present invention is a hydrogenated block copolymer having a hydrogenated aromatic vinyl polymer block unit, which is a hydrogenated product of a polymer block comprising at least one aromatic vinyl monomer unit, and a hydrogenated conjugated diene polymer block unit, which is a hydrogenated product of a polymer block comprising at least one conjugated diene monomer unit. The hydrogenated block copolymer has at least two hydrogenated aromatic vinyl polymer block units and at least one hydrogenated conjugated diene polymer block unit. The term "block" refers to a copolymer polymerization segment that exhibits microphase separation from structurally or compositionally distinct polymerization segments of the copolymer. For example, "having at least two block units" refers to the presence of at least two copolymer polymerization segments that exhibit microphase separation from structurally or compositionally distinct polymerization segments in the hydrogenated block copolymer. The aromatic vinyl monomer that serves as the raw material for the aromatic vinyl monomer unit is a monomer represented by the following general formula (1):
[0016] In general formula (1), R is hydrogen or an alkyl group. The alkyl group may be an alkyl group that is mono- or poly-substituted with a functional group such as a halo group (halogen), a nitro group, an amino group, a hydroxy group, a cyano group, a carbonyl group, or a carboxyl group. The alkyl group preferably has 1 to 6 carbon atoms. Of these, R is preferably hydrogen.
[0017] In general formula (1), Ar is a phenyl group, a halophenyl group, an alkylphenyl group, an alkylhalophenyl group, a naphthyl group, a pyridinyl group, or an anthracenyl group. Among these, Ar is preferably a phenyl group or an alkylphenyl group, and more preferably a phenyl group.
[0018] Examples of the aromatic vinyl monomer include styrene, α-methylstyrene, vinyltoluene (including all isomers, preferably p-vinyltoluene), ethylstyrene, propylstyrene, butylstyrene, vinylbiphenyl, vinylnaphthalene, vinylanthracene (including all isomers), and mixtures thereof, with styrene being preferred.
[0019] The conjugated diene monomer serving as a raw material for the conjugated diene monomer unit may be any monomer having two conjugated double bonds, such as 1,3-butadiene, 2-methyl-1,3-butadiene (isoprene), 2-methyl-1,3-pentadiene, analogous compounds thereof, and mixtures thereof, with 1,3-butadiene being preferred.
[0020] Polybutadiene, a polymer of 1,3-butadiene, can contain either the 1,2 configuration, which upon hydrogenation gives the equivalent of a 1-butene repeat unit, or the 1,4 configuration, which upon hydrogenation gives the equivalent of an ethylene repeat unit.
[0021] A preferred example of the hydrogenated aromatic vinyl polymer block unit is a block unit consisting of hydrogenated polystyrene, which is a hydrogenated product of a polystyrene block unit consisting of a styrene monomer unit, and a preferred example of the hydrogenated conjugated diene polymer block unit is a block unit consisting of hydrogenated polybutadiene, which is a hydrogenated product of a butadiene polymer block consisting of a butadiene monomer unit. A preferred embodiment of the hydrogenated block copolymer is a hydrogenated triblock or pentablock copolymer of styrene and butadiene, which preferably does not contain any other functional group or structural modifier.
[0022] The content of the hydrogenated aromatic vinyl polymer block unit is 30 to 80 mol %, preferably 40 to 75 mol %, relative to the cyclic polyolefin (A). When the ratio of the hydrogenated aromatic vinyl polymer block unit is equal to or greater than the above-mentioned lower limit, the rigidity is not reduced, and when it is equal to or less than the above-mentioned upper limit, the toughness is improved and the brittleness is not deteriorated.
[0023] The content of the hydrogenated conjugated diene polymer block units is 20 to 70 mol %, preferably 25 to 60 mol %, relative to the cyclic polyolefin (A). If the ratio of the hydrogenated conjugated diene polymer block units is equal to or greater than the above-mentioned lower limit, toughness is improved and brittleness is not deteriorated, while if the ratio is equal to or less than the above-mentioned upper limit, rigidity is not reduced.
[0024] In the present invention, the term "cyclic" in cyclic polyolefin refers to an alicyclic structure formed by hydrogenation of the aromatic ring contained in the hydrogenated aromatic vinyl polymer block unit.
[0025] Hydrogenated block copolymers are produced by hydrogenation of block copolymers, including triblock, multiblock, tapered block, and star block copolymers, such as SBS, SBSBS, SIS, SISIS, and SISBS (where S is polystyrene, B is polybutadiene, and I is polyisoprene).
[0026] The hydrogenated block copolymer contains an aromatic vinyl polymer segment at each end, resulting in at least two hydrogenated aromatic vinyl polymer block units, and at least one hydrogenated conjugated diene polymer block unit between the two hydrogenated aromatic vinyl polymer block units.
[0027] The block copolymer comprising the hydrogenated block before hydrogenation may contain additional blocks, which may be attached at any position along the block polymer backbone. Thus, linear blocks include, for example, SBS, SBSB, SBSBS, and SBSBSB. The copolymer may also be branched, with the polymer chains attached at any position along the copolymer backbone.
[0028] The lower limit of the weight average molecular weight (Mw) of the hydrogenated block copolymer is preferably 30,000 or more, more preferably 40,000 or more, even more preferably 45,000 or more, and particularly preferably 50,000 or more. The upper limit of Mw is preferably 120,000 or less, more preferably 100,000 or less, even more preferably 95,000 or less, particularly preferably 90,000 or less, extremely preferably 85,000 or less, and most preferably 80,000 or less. If Mw is above the lower limit, mechanical strength does not decrease, and if it is below the upper limit, molding processability does not deteriorate. Here, the Mw of the cyclic polyolefin (A) is determined using gel permeation chromatography (GPC) under the same measurement conditions as for the styrene-based block copolymer (C) described below.
[0029] The hydrogenation level of the hydrogenated block copolymer is preferably 90% or more for hydrogenated aromatic vinyl polymer block units and 95% or more for hydrogenated conjugated diene polymer block units; more preferably 95% or more for hydrogenated aromatic vinyl polymer block units and 99% or more for hydrogenated conjugated diene polymer block units; even more preferably 98% or more for hydrogenated aromatic vinyl polymer block units and 99.5% or more for hydrogenated conjugated diene polymer block units; and particularly preferably 99.5% or more for hydrogenated aromatic vinyl polymer block units and 99.5% or more for hydrogenated conjugated diene polymer block units. The hydrogenation level of the hydrogenated aromatic vinyl polymer block units refers to the proportion of the aromatic vinyl polymer block units saturated by hydrogenation, and the hydrogenation level of the hydrogenated conjugated diene polymer block units refers to the proportion of the conjugated diene polymer block units saturated by hydrogenation. Such a high level of hydrogenation is preferred for heat resistance and transparency. The hydrogenation level of component (A) is determined using proton NMR.
[0030] The melt flow rate (MFR) of component (A) of the present invention is preferably 0.1 g / 10 min or more, more preferably 0.2 g / 10 min or more, from the viewpoint of molding method and appearance of molded articles. Furthermore, from the viewpoint of material strength, it is preferably 200 g / 10 min or less, more preferably 100 g / 10 min or less, and even more preferably 50 g / 10 min or less. The MFR was measured in accordance with ISO R1133 under the conditions of a measurement temperature of 230°C and a measurement load of 2.16 kg.
[0031] The component (A) of the present invention may be used alone or in combination of two or more different types having different monomer unit compositions, physical properties, etc. As the component (A) of the present invention, a commercially available product can be used, and a specific example is ZELAS (registered trademark) manufactured by Mitsubishi Chemical Corporation.
[0032] <Alicyclic saturated hydrocarbon polymer (B) (component (B))> The alicyclic saturated hydrocarbon polymer (B) (component (B)) is a saturated hydrocarbon having a hydrocarbon main chain and an alicyclic structure. Specific examples include hydrogenated petroleum resins obtained by hydrogenating aromatic petroleum resins, resins obtained by hydrogenating petroleum resins containing aromatic compounds, and resins obtained by hydrogenating alicyclic hydrocarbon resins having unsaturated bonds. This hydrogenation converts the aromatic rings into saturated alicyclic structures. This alicyclic saturated hydrocarbon polymer (B) has good compatibility with the above-mentioned cyclic polyolefin (A), and can suppress transpiration and improve flexibility.
[0033] Examples of the component (B) of the present invention include hydrogenated terpene resins (Yasuhara Chemical Co., Ltd.: Clearon (registered trademark) P, M, K series), hydrogenated rosin and hydrogenated rosin ester resins (Rika Finetech Co., Ltd.: Foral (registered trademark) AX, Foral 105, Arakawa Chemical Industries, Ltd.: Pencel (registered trademark) A, Arakawa Chemical Industries, Ltd.: Ester Gum (registered trademark) H, Arakawa Chemical Industries, Ltd.: Super Ester (registered trademark) A series), disproportionated rosin and disproportionated rosin ester resins (Arakawa Chemical Industries, Ltd.: Pine Crystal (registered trademark) series), and C5 petroleum resins obtained by copolymerizing C5 fractions such as pentene, isoprene, piperine, and 1,3-pentadiene produced by thermal cracking of petroleum naphtha. Hydrogenated dicyclopentadiene resins (Escoretz (registered trademark) 5300, 5400 series manufactured by Dawnex Co., Ltd., Eastotac (registered trademark) H series manufactured by Eastman Chemical Japan Co., Ltd.), partially hydrogenated aromatic-modified dicyclopentadiene resins (Escoretz (registered trademark) 5600 series manufactured by Thornex Co., Ltd.), resins obtained by copolymerizing C9 fractions such as indene, vinyltoluene, α- or β-methylstyrene produced by thermal cracking of petroleum naphtha, hydrogenated C9 petroleum resins (Arcon (registered trademark) P and M series manufactured by Arakawa Chemical Industries, Ltd.), and resins obtained by hydrogenating copolymerized petroleum resins of the above-mentioned C5 fraction and C9 fraction (Imave (registered trademark) series manufactured by Idemitsu Kosan Co., Ltd.). These alicyclic saturated hydrocarbon polymers may be used alone or in combination of two or more.
[0034] The softening point of the component (B) of the present invention, as measured by JIS K6823 (ring and ball method), is preferably 100°C or higher, more preferably 115°C or higher, and particularly preferably 125°C or higher, and is preferably 180°C or lower, more preferably 175°C or lower, even more preferably 170°C or lower, and particularly preferably 165°C or lower. When the softening point is equal to or higher than the above-mentioned lower limit, the suppression of transpiration tends to be further improved. On the other hand, when the softening point is equal to or lower than the above-mentioned upper limit, the moldability tends to be good.
[0035] <Styrene-based Block Copolymer (C) (Component (C))> The styrene-based block copolymer (C) (component (C)) of the present invention is a hydrogenated styrene-based copolymer. The styrene-based copolymer of the present invention is produced by hydrogenating a styrene-based copolymer such as polystyrene, a styrene / α-methylstyrene copolymer, or a styrene / vinylnaphthalene copolymer. Among these, hydrogenated polystyrene, which is a hydrogenated polystyrene, is preferred.
[0036] The lower limit of the weight average molecular weight (Mw) of component (C) of the present invention is preferably 100,000 or more. The upper limit of Mw is preferably 400,000 or less, more preferably 300,000 or less, and even more preferably 200,000 or less. If Mw is equal to or greater than the above-mentioned lower limit, mechanical strength will not decrease, and if it is equal to or less than the above-mentioned upper limit, moldability will not deteriorate.
[0037] Here, the Mw of the styrene-based block copolymer (C) is a polystyrene-equivalent value measured using GPC under the following conditions: Instrument: "GPC HLC-832GPC / HT" manufactured by Tosoh Corporation Column: Three "AD806M / S" columns manufactured by Showa Denko K.K. (The columns were calibrated using monodisperse polystyrenes manufactured by Tosoh Corporation (A500, A2500, F1, F2, F4, F10, F20, F40, and F288, each at 0.5 mg / mL), and the elution volume and the logarithm of the molecular weight were approximated by a cubic equation.) Detector: "1A Infrared Spectrophotometer" manufactured by MIRAN (measurement wavelength: 3.42 μm) Solvent: o-dichlorobenzene Temperature: 135° C. Flow rate: 1.0 mL / min Injection volume: 200 μL Concentration: 20 mg / 10 mL
[0038] The hydrogenation level of component (C) of the present invention is preferably 90% or higher, more preferably 95% or higher, and even more preferably 97% or higher. The hydrogenation level of the hydrogenated aromatic vinyl polymer refers to the percentage of the aromatic vinyl polymer saturated by hydrogenation. Such a high level of hydrogenation is preferred for heat resistance and transparency. The hydrogenation level of the styrene-based block copolymer (C) is determined using proton NMR.
[0039] The MFR of component (C) of the present invention is preferably 0.1 g / 10 min or more, more preferably 0.2 g / 10 min or more, from the viewpoint of the molding method and the appearance of the molded article. Furthermore, from the viewpoint of material strength, it is preferably 200 g / 10 min or less, more preferably 100 g / 10 min or less, and even more preferably 50 g / 10 min or less. The MFR was measured in accordance with ISO R1133 under the conditions of a measurement temperature of 230°C and a measurement load of 2.16 kg.
[0040] The component (C) of the present invention may be used alone or in combination of two or more types differing in the composition of the monomer units, physical properties, etc.
[0041] <Polymer Composition> The liquid container of the present invention contains a polymer composition containing the above-mentioned component (A), and may also contain a component (B) or a component (C). The content of the component (A) is preferably 72 parts by weight or more, more preferably 75 parts by weight or more, per 100 parts by weight of the polymer composition. The upper limit of the content of the component (A) may be 100 parts by weight, but when other components such as the component (B) or the component (C) are added, 95 parts by weight is preferred.
[0042] When the component (B) is contained, the content of the component (B) is preferably 2 parts by weight or more, more preferably 5 parts by weight or more, and even more preferably 7 parts by weight or more, relative to 100 parts by weight of the polymer composition. Furthermore, when the component (B) is contained, the upper limit of the content of the component (B) is preferably 25 parts by weight or less, more preferably 20 parts by weight or less, relative to 100 parts by weight of the polymer composition. By keeping the content within the above range, squeezability (flexibility) and suppression of transpiration can be improved.
[0043] When the component (C) is contained, the content of the component (C) is preferably 2 parts by weight or more, more preferably 5 parts by weight or more, per 100 parts by weight of the polymer composition. Furthermore, when the component (C) is contained, the upper limit of the content of the component (C) is preferably 25 parts by weight or less, more preferably 20 parts by weight or less, per 100 parts by weight of the polymer composition. By keeping the content within the above range, squeezability (flexibility) and suppression of transpiration can be improved.
[0044] From the viewpoint of improving squeezability (flexibility) and suppression of transpiration, the polymer composition preferably contains component (A), component (B), and component (C), and the content ratio (weight ratio) of these components is preferably within the range of component (A) / component (B) / component (C)=72 to 95 / 2 to 25 / 2 to 25, more preferably 75 to 85 / 5 to 20 / 5 to 15.
[0045] <Other Components> The polymer composition of the present invention can contain, as other components, compounding agents commonly used in resin compositions, to the extent that the effects of the present invention are not impaired. Examples of such compounding agents include heat stabilizers, UV absorbers, light stabilizers, antioxidants, antistatic agents, crystal nucleating agents, rust inhibitors, inorganic fillers, foaming agents, and pigments. Of these, it is preferable to contain an antioxidant, particularly a phenol-based, sulfur-based, or phosphorus-based antioxidant. It is preferable to contain 0.01 to 2 parts by weight of the antioxidant per 100 parts by weight of the polymer composition.
[0046] Furthermore, resin components and elastomer components other than components (A), (B), and (C) may be contained within a range that does not impair the effects of the present invention. Examples of such resin components include polyethylene resins, polypropylene resins, ethylene / α-olefin copolymer resins, propylene / α-olefin copolymer resins, ethylene / vinyl acetate copolymer resins, ethylene / acrylic acid ester copolymer resins, ethylene / (meth)acrylic acid copolymer resins, polystyrene resins, polyvinyl chloride resins, polyester resins, polyamide resins, ethylene / vinyl alcohol copolymers, acrylic resins, and petroleum resins.
[0047] Examples of the elastomer component include olefin elastomers, styrene elastomers, polyester elastomers, urethane elastomers, acrylic elastomers, and nylon elastomers.
[0048] The other components may be added to component (A), component (B), or component (C) by a kneading method commonly used for melt-kneading thermoplastic resins, or may be dissolved in an organic solvent together with component (A), component (B), or component (C) and mixed.
[0049] <Method for producing polymer composition> The polymer composition of the present invention can be produced by kneading component (A), and, if necessary, component (B), component (C), and the other components described above, in a conventional manner using a conventional extruder, Banbury mixer, roll, Brabender Plastograph, Kneader Brabender, or the like. Among these production methods, it is preferable to use an extruder, in particular a twin-screw extruder. When the polymer composition of the present invention is produced by kneading using an extruder or the like, it is melt-kneaded in a heated state usually at 220 to 320°C, preferably 250 to 300°C.
[0050] [Product, method of the present invention, etc.] In the present invention, the "product" preferably refers to a state in which an aqueous liquid preparation containing a PGF2α derivative is stored in a thermoplastic resin container containing a specific cyclic polyolefin. The present invention also includes a method for preventing a decrease in the content of the PGF2α derivative in an aqueous liquid preparation by storing the aqueous liquid preparation containing a PGF2α derivative in a thermoplastic resin container containing a specific cyclic polyolefin. Furthermore, the present invention also includes a thermoplastic resin container made of a specific polymer composition containing a specific cyclic polyolefin for storing an aqueous liquid preparation containing a PGF2α derivative.
[0051] [Other Components in Aqueous Liquid Preparations] The aqueous liquid preparation of the present invention may contain a surfactant, preferably a nonionic surfactant. For example, it may contain polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hydrogenated castor oil, polyoxyethylene castor oil, etc. Specific examples include polyoxyethylene sorbitan fatty acid esters such as polysorbate 60, polysorbate 65, and polysorbate 80, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil 40, polyoxyethylene hydrogenated castor oil 60, polyoxyethylene (160) polyoxypropylene (30) glycol, polyoxyethylene (200) polyoxypropylene (70) glycol, polyoxyl 40 stearate, and polyethylene glycol monostearate, but are not limited thereto. The surfactants may be used alone or in any combination of two or more.
[0052] The aqueous liquid preparation of the present invention may contain a pH adjuster, such as hydrochloric acid, acetic acid, sulfuric acid, polyphosphoric acid, propionic acid, oxalic acid, gluconic acid, malic acid, succinic acid, fumaric acid, lactic acid, tartaric acid, sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, monoethanolamine, triethanolamine, or diisopropanolamine. The pH adjusters may be used alone or in any combination of two or more.
[0053] The aqueous liquid preparation of the present invention may contain a buffer. Examples of the buffer include boric acid, borax, potassium tetraborate, potassium metaborate, ammonium borate, and other borates or hydrates thereof; phosphates or hydrates thereof such as disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, trisodium phosphate, dipotassium phosphate, calcium monohydrogen phosphate, calcium dihydrogen phosphate, and other phosphates; carbonates or hydrates thereof such as sodium bicarbonate, sodium carbonate, ammonium carbonate, potassium carbonate, calcium carbonate, potassium bicarbonate, and magnesium carbonate; citrates or hydrates thereof such as sodium citrate, potassium citrate, calcium citrate, sodium dihydrogen citrate, and disodium citrate; acetates such as ammonium acetate, potassium acetate, calcium acetate, and sodium acetate. The buffer may be used alone or in any combination of two or more.
[0054] The aqueous liquid preparation of the present invention may contain an isotonicity agent. Examples of the isotonicity agent include, but are not limited to, sodium bisulfite, sodium sulfite, potassium chloride, calcium chloride, sodium chloride, magnesium chloride, sodium thiosulfate, magnesium sulfate, glycerin, concentrated glycerin, propylene glycol, Macrogol 400, Macrogol 4000, Macrogol 6000, D-mannitol, etc. The isotonicity agent may be used alone or in any combination of two or more.
[0055] The aqueous liquid preparation of the present invention may contain a chelating agent or a stabilizer. Examples thereof include, but are not limited to, ethylenediaminediacetic acid, ethylenediaminetriacetic acid, ethylenediaminetetraacetic acid (EDTA, edetic acid), salts thereof, and hydrates of the salts, sodium hydrogen sulfite, glycerin monostearate, cyclodextrin, monoethanolamine, etc. The chelating agent or stabilizer may be used alone or in any combination of two or more.
[0056] The aqueous liquid preparation of the present invention may contain a preservative, bactericide, or antibacterial agent. Examples include, but are not limited to, zinc chloride, sodium benzoate, ethanol, benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, sorbic acid, potassium sorbate, sodium sorbate, chlorobutanol, sodium dehydroacetate, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, and propyl parahydroxybenzoate. The preservative, bactericide, or antibacterial agent may be used alone or in any combination of two or more.
[0057] The aqueous liquid preparation of the present invention may further contain a sodium salt and / or a potassium salt. For example, sodium salt and potassium salt are used. Examples of sodium salts include sodium chloride, disodium monohydrogen phosphate, monosodium dihydrogen phosphate, sodium sulfate, sodium bicarbonate, sodium carbonate, sodium citrate, sodium hydroxide, etc. Preferred are sodium chloride, sodium monohydrogen phosphate, and sodium dihydrogen phosphate, more preferably sodium chloride. Examples of potassium salts include potassium chloride, dipotassium monohydrogen phosphate, monopotassium dihydrogen phosphate, potassium acetate, etc. Preferred are potassium chloride, dipotassium monohydrogen phosphate, and monopotassium dihydrogen phosphate, more preferably potassium chloride. One or more types of sodium salts and / or potassium salts can be used.
[0058] In addition to the above-mentioned components, the aqueous liquid preparation of the present invention may contain a base such as water, other active ingredients, and other additives (carriers, solubilizers, antioxidants, solvents, solubilizers, suspending agents, flavorings / fragrances, cooling agents, sugars, sugar alcohols, thickeners), etc., within the range that does not impair the effects of the present invention. These optional ingredients may be added in normal amounts within the range that does not impair the effects of the present invention. The water used as a base in the preparation of the eye drops is not particularly limited as long as it is water that can be used for ophthalmic preparations, and for example, purified water can be used. The mixing order and mixing method of the components are not particularly limited, and the components may be dissolved in water by a known preparation method.
[0059] The PGF2α derivative used in the present invention may be, for example, a commercially available product, or may be a synthetic product.
[0060] [Suppression of adsorption of PGF2α derivative to container, suppression of decrease in content of PGF2α derivative] In the present invention, the method for quantifying the PGF2α derivative in the aqueous liquid preparation can be, for example, measuring the content using high performance liquid chromatography (HPLC), but is not limited to this method. As described in the Examples below, the content can be calculated as a percentage based on the content of the PGF2α derivative in the aqueous liquid preparation before storage in the container, and the content after storage at 40°C or 60°C for a certain period of time. Furthermore, in the present invention, the PGF2α derivative being easily adsorbed to a container preferably means that the content of the PGF2α derivative is significantly reduced when the aqueous liquid containing the PGF2α derivative is stored in the container, and for example, when the aqueous liquid containing the PGF2α derivative is 0.0015 w / v%, the content of the PGF2α derivative is reduced by 5% or more, more preferably 10% or more, after storage in a polyolefin container, such as a polyethylene (PE) or polypropylene (PP) container, preferably at 40°C for 6 weeks, more preferably at 60°C for 1 week, but this is not limited to this.
[0061] The aqueous liquid preparation of the present invention preferably has an osmotic pressure ratio of 0.9 to 1.1, more preferably 1.0 to 1.1. The osmotic pressure can be measured by the method described in Section 2.47 Osmolality Measurement (Osmolality Measurement) of the Japanese Pharmacopoeia (18th Edition), or by a method known in the art.
[0062] The aqueous liquid preparation of the present invention preferably has a pH of about 5.0 to 8.0, more preferably about 5.5 to 7.0, and even more preferably about 5.7 to 6.3. The osmotic pressure ratio and pH can be adjusted by methods known in the art using the above-mentioned or known pH adjusters, isotonicity agents, salts, etc.
[0063] The product or aqueous liquid preparation of the present invention is preferably administered to individuals (animals) who have or are at risk of developing the above-mentioned symptoms of glaucoma or ocular hypertension, preferably individuals who have glaucoma or ocular hypertension. The individual is preferably a mammal such as a human, mouse, rat, rabbit, dog, cat, cow, horse, pig, or monkey, and is particularly preferably, but not limited to, a human.
[0064] The dosage and frequency of administration of the product or aqueous liquid of the present invention can be appropriately selected depending on the symptoms of the patient, etc. Usually, about one drop is administered to the eye of an adult about once a day.
[0065] The present invention will be explained in more detail below with reference to examples, comparative examples, test examples, etc., but the present invention is not limited to the following examples as long as it does not deviate from the gist of the invention. The values of various production conditions and evaluation results in the following examples represent preferred upper or lower limit values in the embodiments of the present invention, and preferred ranges may be defined by a combination of the above-mentioned upper or lower limit values and the values in the following examples or values between the examples.
[0066] [Calculation formula for PGF2α derivative content]
[0067] (Product Preparation Method) An aqueous liquid preparation and a thermoplastic resin container were prepared by the following method to obtain the product of the present invention.
[0068] Example 1: Preparation of aqueous liquid preparation used in the present invention An aqueous liquid preparation used in the present invention was obtained by the method described below. Appropriate amounts of sodium edetate hydrate, benzalkonium chloride, a buffer, and an isotonicity agent were dissolved in purified water, and a solution of tafluprost dissolved in purified water using polysorbate 80 was added. A pH adjuster was further used to prepare an aqueous liquid preparation with an osmotic pressure ratio of about 1 and a pH of about 6.0. The detailed formulation of the aqueous liquid preparation is as shown in Table 2 below.
[0069] [Physical Properties] <Ratio of Polymer Blocks of Cyclic Polyolefin (A)> [Measurement by Carbon NMR] Apparatus: AVANCE 400 Spectrometer manufactured by Bruker Solvent: o-Dichlorobenzene-h 4 / p-dichlorobenzene-d 4 Mixed solvent: Concentration: 0.3 g / 2.5 mL Measurement: 13 C-NMR Resonance frequency: 400 MHz Number of accumulations: 1536 Flip angle: 45 degrees Data acquisition time: 1.5 seconds Pulse repetition time: 15 seconds Measurement temperature: 100°C 1 H irradiation: complete decoupling
[0070] <Hydrogenation Level> [Measurement by Proton NMR] Apparatus: "400YH Spectrometer" manufactured by JASCO Corporation Solvent: deuterated chloroform Concentration: 0.045 g / 1.0 mL Measurement: 1 H-NMR Resonance frequency: 400 MHz Number of accumulations: 8 Measurement temperature: 18.5°C Hydrogenation level of styrene-based block copolymer (C): reduction rate of integral value of 6.8 to 7.5 ppm Hydrogenation level of hydrogenated aromatic vinyl polymer block unit of cyclic polyolefin (A): reduction rate of integral value of 6.8 to 7.5 ppm Hydrogenation level of hydrogenated conjugated diene polymer block unit of cyclic polyolefin (A): reduction rate of integral value of 5.7 to 6.4 ppm
[0071] (Raw Materials) (Cyclic Polyolefin (A))...ZELAS manufactured by Mitsubishi Chemical Corporation Density (ASTM D792): 0.94 g / cm 3MFR (230°C, 2.16 kg): 0.5 g / 10 min Hydrogenated aromatic vinyl polymer block unit: hydrogenated polystyrene having a content of 50 mol% and a hydrogenation level of 98.7% Hydrogenated conjugated diene polymer block unit: hydrogenated polybutadiene having a content of 50 mol% and a hydrogenation level of 99.5% or more Block structure: pentablock structure, total hydrogenation level: 99.2% (alicyclic saturated hydrocarbon polymer (B)) Density (ASTM D792): 1.00 g / cm 3 C9 hydrogenated petroleum resin Softening temperature: 115°C (styrene-based block copolymer (C)) Hydrogenated styrene-butadiene-styrene block copolymer, aromatic vinyl polymer block unit (polystyrene block unit): 30% by weight, butadiene hydrogenation rate: 99% or more, Mw: 90,000
[0072] (Examples 2 and 3: Production of thermoplastic resin container containing cyclic polyolefin of the present invention) A thermoplastic resin container containing cyclic polyolefin (SB) of the present invention was obtained by the method described below. The internal volume of the container was 7.8 mL.
[0073] The components (A), (B), and (C) were blended in the amounts shown in Table 3 below, and the mixture was melt-kneaded in a twin-screw extruder at a temperature ranging from 220°C to 280°C to obtain thermoplastic resin pellets. The resulting pellets were used to produce the SB container of the present invention by injection blow molding.
[0074] (Comparative Examples 1 and 2: Production of PP container and PE container) A polypropylene (PP) container was used as Comparative Example 1, and a polyethylene (PE) container was used as Comparative Example 2. These containers were each produced by injection blow molding. The internal volume of these containers was also 7.8 mL, the same as that of the SB container. In the following Test Examples 1 and 2, the aqueous liquid preparations and thermoplastic resin containers (SB, PP, and PE) produced in the above-mentioned Examples and Comparative Examples were used.
[0075] [Test Example 1] Confirmation of the effect of reducing the content of PGF2α derivative in aqueous liquid preparations and the effect of inhibiting adsorption to containers under storage conditions at 40°C. Under the condition of 40°C, approximately 2.5mL of the aqueous liquid preparation of the present invention was stored in a thermoplastic resin container (SB, PP, and PE) for 6 weeks, and the content of PGF2α derivative in the aqueous liquid preparation was confirmed. The content (%) in the table was calculated as a percentage based on the content of PGF2α derivative in the aqueous liquid preparation before storage in the container, and the content after a certain period of time. The results are shown in Table 4 below (n=2).
[0076] From the contents of Table 4 above, it can be seen that the thermoplastic resin container (SB) containing the cyclic polyolefin of the present invention was able to suppress the decrease in the content of the PGF2α derivative compared to the thermoplastic resin containers (PP and PE) of the comparative examples. In other words, the container of the present invention was able to suppress the adsorption of the PGF2α derivative in the aqueous liquid preparation to the container under accelerated and long-term storage conditions.
[0077] [Test Example 2] Confirmation of the effect of reducing the content of PGF2α derivative in aqueous liquid preparations and the effect of inhibiting adsorption to containers under storage conditions at 60°C About 2.5 mL of the aqueous liquid preparation of the present invention was stored in each thermoplastic resin container (SB, PP, and PE) for one week under conditions of 60°C, and the content of PGF2α derivative in the aqueous liquid preparation was confirmed. The content (%) in the table was calculated in the same manner as in Test Example 1. The results are shown in Table 5 below (n=2).
[0078] From the contents of Table 5 above, it can be seen that the thermoplastic resin container (SB) containing the cyclic polyolefin of the present invention was able to suppress the decrease in the content of the PGF2α derivative compared to the thermoplastic resin containers (PP and PE) of the comparative examples. In other words, the container of the present invention was able to suppress the adsorption of the PGF2α derivative in the aqueous liquid preparation to the container under storage conditions at 60°C.
[0079] The product and container of the present invention are useful for aqueous medical solutions, particularly in the field of ophthalmology and eye drops.
Claims
1. A product in which an aqueous liquid preparation containing a prostaglandin F2α derivative is stored in a thermoplastic resin container containing cyclic polyolefin.
2. A product in which the aqueous liquid preparation containing a prostaglandin F2α derivative is stored in a thermoplastic resin container containing cyclic polyolefin, thereby preventing the decrease in the content of the prostaglandin F2α derivative.
3. The product according to claim 1 or 2, wherein the prostaglandin F2α derivative is one or more selected from the group consisting of tafluprost, latanoprost, isopropyl unoprostone, travoprost, and bimatoprost.
4. The product according to claims 1 to 3, wherein the prostaglandin F2α derivative is tafluprost.
5. The product according to any one of claims 1 to 4, wherein the thermoplastic resin container is a polymer composition containing 72% by weight or more of a cyclic polyolefin having hydrogenated aromatic vinyl polymer block units, which are hydrogenated products of polymer blocks consisting of aromatic vinyl monomer units, and hydrogenated conjugated diene polymer block units, which are hydrogenated products of polymer blocks consisting of conjugated diene monomer units.
6. The product according to claim 5, wherein the polymer composition contains 2% by weight or more and 25% by weight or less of a hydrogenated C9 petroleum resin.
7. The article of claim 5 or 6, wherein the polymer composition comprises from 2% to 25% by weight of a styrenic block copolymer.
8. The product according to any one of claims 1 to 7, wherein the hydrogenated aromatic vinyl polymer block unit constituting the cyclic polyolefin is a hydrogenated polystyrene block unit which is a hydrogenated product of a polystyrene block unit composed of a styrene monomer unit, and the hydrogenated conjugated diene polymer block unit constituting the cyclic polyolefin is a hydrogenated butadiene polymer block unit which is a hydrogenated product of a butadiene polymer block composed of a butadiene monomer unit.
9. The product according to any one of claims 1 to 8, wherein the product is an eye drop.
10. The product according to any one of claims 1 to 9, wherein the aqueous liquid contains a surfactant.
11. A method for suppressing a decrease in the content of a prostaglandin F2α derivative in an aqueous liquid preparation by storing the aqueous liquid preparation in a thermoplastic resin container containing a cyclic polyolefin.
12. A thermoplastic resin container for storing an aqueous liquid preparation containing a prostaglandin F2α derivative, comprising a cyclic polyolefin and a hydrogenated C9 petroleum resin and / or a styrene block copolymer.
Citation Information
Patent Citations
Prostaglandin aqueous eye drop
JP2008189567A
Methods and compositions for treating ocular hypertension and glaucoma
JP2011521943A
Pharmaceutical preparation
JP2019189565A
Molded body for medical use
JP2020180301A
Eye drop container
JP2021177839A
